Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma
- PMID: 39674169
- DOI: 10.1016/j.medj.2024.10.022
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma
Abstract
Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody, significantly reduced exacerbation rates in patients with severe eosinophilic asthma when administered biannually.1 While it offers potential benefits for patient adherence and convenience, the trials showed no improvement in symptoms and lung function. Further research is needed to determine its optimal place in therapy and identify patients who will benefit the most.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.C. reports honoraria for lectures from GSK, Sanofi, AstraZeneca, Vitalaire, Fisher & Paykel, ResMed, and Philips, outside the submitted work.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
